
New treatment option for older patients with blood cancer
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
COVID-19: Everything you need to know about patient and visitor information.
Our research focuses on the regulation of stem cells in haematopoietic and leukaemic cells through genetic and epigenetic studies.
We found that the genes Ap2a2 and Gpsm2 enhance haematopoietic stem cell self-renewal and now study whether their respective dysregulation affects leukaemia.
We constructed an Ap2a2 conditional knockout mouse model, which shows embryonic lethality when constitutively deleted. Haematopoietic specific deletion of Ap2a2 during development and adulthood is being assessed.
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).